Stents liberadores de drogas: ¿hasta dónde ha llegado la evidencia clínica?

Barra lateral del artículo

PDF
Publicado: 10-06-2009
DOI: https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v29i1.1064

Contenido principal del artículo

Daniel Berrocal
Servicio de Hemodinamia. Hospital Italiano de Buenos Aires, Argentina

Resumen

.

Downloads

Download data is not yet available.

Detalles del artículo

Número

Vol. 29 Núm. 1 (2009): Revista del Hospital Italiano de Buenos Aires

Sección

Actualización y avances en investigación
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Cómo citar

1.
Berrocal D. Stents liberadores de drogas: ¿hasta dónde ha llegado la evidencia clínica?. Rev Hosp Ital B.Aires [Internet]. 2009 Jun. 10 [cited 2026 Jun. 6];29(1):37-41. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/1064

Referencias

sousa Je, costa MA, Abizaid Ac, et al. sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. circulation. 2001;104(17):2007-11. DOI: https://doi.org/10.1161/hc4201.098056

Morice Mc, serruys PW, sousa Je, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. n engl J Med. 2002;346(23):1773-80 DOI: https://doi.org/10.1056/NEJMoa012843

schofer J, schlüter M, gershlick AH, et al. sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (e-si Rius). lancet. 2003;362(9390):1093-9 DOI: https://doi.org/10.1016/S0140-6736(03)14462-5

stone gW, ellis sg, cannon l, et al. comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent inpatients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10):1215-23. DOI: https://doi.org/10.1001/jama.294.10.1215

Dawkins KD, grube e, guagliumi g, et al. clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. circulation. 2005;112(21):3306-13. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.552190

liu J, Maehara A, Mintz gs, et al. An integrated tAXus iv, v, and vi intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J cardiol. 2009;103(4):501-6. DOI: https://doi.org/10.1016/j.amjcard.2008.10.010

teirstein Ps, Moses JW, leon MB, et al. use of the sirolimus-eluting Bx velOcitytm stent for failed brachytherapy in recurrent in-stent restenosis: results from the secuRe registry. circulation. 2003;108(suppl iv): iv-409. Abstract 1889. DOI: https://doi.org/10.1016/S0735-1097(03)80206-1

Hayasi B. lAcyR Registry: one year results [internet]. course on revascularization. 2005 mayo ; Paris, Francia. [citado 29/07/09]. Disponible en: http://www.europcronline.com/fo/lecture/view_slide.php?id=2427&start=19

Abizaid A, chan c, Kaul u, et al. "Real world" evaluation of slow-release, polymer-based, paclitaxel-eluting tAXus™ stents in native coronary arteries: the WisDOM international registry. circulation. 2003;108(suppl iv): iv-534. Abstract 2436.

colombo A. the si Rius Bifurcation study. American Heart Association scientific Meeting. 2002 Oct; chicago, usA.

Jiménez-Quevedo P, sabaté M, Angiolillo DJ, et al. long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DiABetes trial. eur Heart J. 2007;28(16):1946-52. DOI: https://doi.org/10.1093/eurheartj/ehm197

serruys PW, Daemen J, Morice M-c, et al. three-year follow-up of the ARts-ii –sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. eurointervention. 2008;3(4):450-9 DOI: https://doi.org/10.4244/EIJV3I4A81

Kastrati A, Mehilli J, von Beckerath n, et al. sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293(2):165-71. DOI: https://doi.org/10.1001/jama.293.2.165

Mehili J. A comparison of cypher and taxus drug eluting stents in left main stenosis (is AR-lM). transcatheter cardiovascular therapeutic.. 2008 Oct.

Morice Mc, colombo A, Meier B, et al. sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the ReAlity trial: a randomized controlled trial. JAMA. 2006;295(8):895-904 DOI: https://doi.org/10.1001/jama.295.8.895

Duda sH, Bosiers M, lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the si ROccO trial. J endovasc ther. 2006;13(6):701-10. DOI: https://doi.org/10.1583/05-1704.1

camenzind e, steg Pg, Wijns W. stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. circulation. 2007;115(11):1440-55. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.666800

stone gW, Moses JW, ellis sg, et al. safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents nengl J Med. 2007;356(10):998-1008. DOI: https://doi.org/10.1056/NEJMoa067193

Kirtane AJ, gupta A, iyengar s, et al. Drug-eluting stent versus bare-metal stent use: meta-analysis of randomized trials and observational studies. circulation 2008;118(s):1040 DOI: https://doi.org/10.1161/circ.118.suppl_18.S_1040